Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Wilsey Asset Management Inc.

Wilsey Asset Management Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 149,405 shares of the biopharmaceutical company’s stock after purchasing an additional 12,078 shares during the quarter. Gilead Sciences accounts for 3.7% of Wilsey Asset Management Inc.’s investment portfolio, making the stock its 15th biggest position. Wilsey Asset Management Inc.’s holdings in Gilead Sciences were worth $9,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of GILD. Advisors Preferred LLC acquired a new position in shares of Gilead Sciences in the second quarter worth about $26,000. Weaver Consulting Group acquired a new position in shares of Gilead Sciences in the first quarter worth about $34,000. Legacy Advisors LLC acquired a new position in shares of Gilead Sciences in the second quarter worth about $37,000. Evolution Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the second quarter worth about $46,000. Finally, Motco lifted its stake in shares of Gilead Sciences by 213.6% in the second quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 470 shares in the last quarter. Institutional investors own 79.67% of the company’s stock.

In related news, Director Olsen Per Wold sold 4,908 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total value of $313,670.28. Following the completion of the transaction, the director now directly owns 102,762 shares of the company’s stock, valued at approximately $6,567,519.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Insiders sold a total of 12,716 shares of company stock valued at $821,299 over the last three months. Corporate insiders own 0.20% of the company’s stock.

Several brokerages recently weighed in on GILD. Morgan Stanley set a $82.00 price objective on Gilead Sciences and gave the company a “hold” rating in a report on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Credit Suisse Group lowered their price objective on Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a report on Wednesday, July 31st. Raymond James set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, August 23rd. Finally, Citigroup set a $78.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $82.24.

Shares of NASDAQ:GILD traded up $0.22 during trading on Wednesday, hitting $65.52. 3,000,364 shares of the company traded hands, compared to its average volume of 5,795,885. The stock has a market capitalization of $83.05 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 3.03 and a beta of 1.10. The business’s fifty day moving average is $64.23 and its 200-day moving average is $65.36. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $76.44. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The business’s revenue was down 2.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.91 earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 6.67 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date was Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: What is the market perform rating?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.